Johnson & Johnson’s Coronavirus Vaccine Candidate Enters Phase 3 Trials
- September 24, 2020
The Washington Post (9/23, Johnson) reports Johnson & Johnson’s coronavirus vaccine candidate is now in phase 3 trials. Johnson & Johnson’s candidate differs from others that have previously entered phase 3 trials in that it would only require a single dose. Paul Stoffels, chief scientific officer of the company, “predicted that there may be enough data to have results by the end of the year and said the company plans to manufacture 1 billion doses next year.”
Reuters (9/23, Steenhuysen) reports if effective, Johnson & Johnson’s vaccine “could simplify distribution of millions of doses compared with leading rivals requiring two doses.” Dr. Dan Barouch, a Harvard researcher who helped the design the vaccine, said, “The benefits of a single-shot vaccine are potentially profound in terms of mass immunization campaigns and global pandemic control.”
CNN (9/23, Mascarenhas) reports Johnson & Johnson will run trials “in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the United States.”
The Hill (9/23, Sullivan) and the Wall Street Journal (9/23, Loftus, Subscription Publication) also cover the story.